This is interesting.
Oral supplementation with probiotic L. reuteri NCIMB 30242 increases mean circulating 25-hydroxyvitamin D: a post-hoc analysis of a randomized controlled trial
Mitchell L. Jones, MD, PhD1,2,†, Christopher J. Martoni, PhD2,† and Satya Prakash, PhD1,2
Biomedical Technology and Cell Therapy Research Laboratory, Department of Biomedical Engineering and Physiology, Artificial Cells and Organs Research Centre, Faculty of Medicine, McGill University, 3775 University St, Montreal, QC, H3A 2B4, Canada
Abstract
Context: Low serum 25-hydroxyvitamin D is a risk factor for osteoporosis, cardiovascular disease, diabetes and cancer. Disruption of non-cholesterol sterol absorption due to cholesterol lowering therapies may result in reduced fat soluble vitamin absorption.
Objective: We have previously reported on the cholesterol lowering efficacy and reduced sterol absorption of probiotic bile salt hydrolase active L. reuteri NCIMB 30242; however, the effects on fat soluble vitamins was previously unknown and the objective of the present study.
Design, Settings, Patients and Intervention: The study was double-blind, placebo-controlled, randomized, parallel-arm, multi-center lasting 13 weeks. 127 otherwise healthy hypercholesterolemic adults with LDL-cholesterol >3.4 mmol/l, triglycerides <4.0 mmol/l and body mass index of 22-32 kg/m2 were included. Subjects were recruited from 6 private practices in Prague, CZ and randomized to consume L. reuteri NCIMB 30242 or placebo capsules over a 9-week intervention period.
Outcome measures: The primary outcome measure was the change in serum LDL-cholesterol over the 9-week intervention. Analysis of fat soluble vitamins at Weeks 0 and 9 were performed post-hoc.
Results: There were no significant differences between L. reuteri NCIMB 30242 and placebo capsule groups in serum vitamin A, vitamin E, β-carotene or dietary intake over the intervention period (P>0.05). L. reuteri NCIMB 30242 increased serum 25-hydroxyvitamin D by 14.9 nmol/l or 25.5% over the intervention period, which was a significant mean change relative to placebo of 17.1 nmol/l or 22.4% respectively (P=0.003).
Conclusions: To our knowledge this is the first report of increased circulating 25-hydroxyvitamin D in response to oral probiotic supplementation.
L. reuteri NCIMB 30242 is commercially available as "Cardioviva" (marketed as a cardiovascular supplement, as L. reuteri NCIMB 30242 has cholesterol lowering activity).
Perhaps other Lactobacillus strains (or other supplements such as certain prebiotics that reduce gut pH) would have a similar effect?
http://www.nutraingr...irst-human-data
“In retrospect there are reports of reduced intestinal pH (a result of lactic acid production) resulting in increased vitamin D absorption and 7-DHC is a common precursor to both cholesterol and vitamin D. Increased plasma deconjugated bile acids and reduced plasma non-cholesterol sterols campesterol, sitosterol, and stigmasterol suggest an effect on sterol absorption and a novel cholesterol reducing mechanism of action.
“The observation of significantly increased 25(OH)D despite no between group differences in dietary intake or seasonality of the intervention period is significant, as to our knowledge this is the first report of fat soluble vitamin status in response to a BSH-active probiotic and the first report of increased levels of circulating 25(OH)D in response to oral supplementation with any probiotic.
“In short, we believe it is possible that more vitamin D is being absorbed or that more precursor is being synthesized,” he said.
Dr Jones added that it is highly likely that delivery of the strain and vitamin D together would result in greater increases, but this is yet to be shown.
Edited by blood, 07 July 2013 - 06:31 AM.
